Entera Bio Ltd. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Entera Bio Ltd. on June 15, 2022. The filing discloses a material corporate event regarding the departure of a senior executive and director.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to the compensation package for the departing executive:
- One-time cash separation payment: NIS 537,600 (approximately $155,900).
- Accrued benefits payment: Approximately NIS 737,771 (approximately $213,952).
- Total estimated cash payout: Approximately $369,852 (subject to mandatory deductions and debts owed).
Material Changes
The primary material change is the resignation of Dr. Phillip Schwartz, who served as President of Research & Development and a member of the Board of Directors.
- Effective Dates: Resignation from the Board is effective June 15, 2022; resignation from the officer role is effective July 21, 2022.
- Reason for Departure: The resignation was not the result of any disagreement with the Company.
- Equity Acceleration: Subject to shareholder approval, Dr. Schwartz receives full acceleration of 100,000 options granted in 2021. His 2017 option grant (357,500 shares) and the 2021 grant will remain exercisable post-separation.
Outlook, Risks, and Contingencies
Future Arrangements: Subject to shareholder approval, Dr. Schwartz will enter into a consulting agreement to provide business development services regarding specific scientific matters. This agreement allows for termination by either party with 14 days' notice.
Shareholder Voting Restrictions: Until the day following the 2023 annual general meeting, Dr. Schwartz has agreed not to vote against the Board's recommendations regarding director elections, removals, or proposals at the 2022 shareholder meeting without written Board consent.
Risks: The filing notes that the separation payments and equity acceleration are contingent upon approval by the Company's shareholders.
Key Facts for Investor Verification
- Verify the outcome of the shareholder vote required to approve the separation agreement, equity acceleration, and consulting arrangement.
- Confirm the timeline for the transition of R&D leadership following Dr. Schwartz's departure on July 21, 2022.
- Review the full text of the Separation Agreement (Exhibit 10.1) for specific details on the consulting scope and non-compete provisions.
- Monitor future filings for the appointment of a new President of R&D and any changes to the Board composition.